Page 3 - Developmental Cell News Today

Scientists at the University of Washington are taking stem cell research to a new level by working to regenerate something people often take for granted: our teeth.

While kidney also exhibits gender-related distinctions, the hormones and underlying factors influencing these distinctions are quite distinct from those influencing the kidney.

New York, Sep 6 (IANS) Females are known to be more resilient to kidney disease and injury, compared to males. Researchers have in a mice study now pointed

Females are known to be more resilient to kidney disease and injury, compared to males. Researchers have in a mice study now pointed out the role of testosterone, a male sex hormone.A team at University of Southern California (USC) found not ...

Female kidneys are known to be more resilient to disease and injury, but males need not despair. A new USC Stem Cell-led study published in Developmental Cell describes not only how sex hormones drive differences in male and female mouse kidneys, but also how lowering testosterone can "feminize" this organ and improve its resilience.

Another departure from thew mundane.....Trump yelled something....Biden walked slowly....McConnell forget something.....and Florida took a big hit. But I will not be reporting on any of that rather I will give you the news that time will forget. I start with the Yuk Factor..... The call went out to Dr. Sanjaya Senanayake, an infectious diseases physician…

2 posts published by lobotero on September 2, 2023

Researchers at the University of Texas MD Anderson Cancer Center published two studies this week on a new approach that could improve treatment for patients with pancreatic cancer. The preclinical studies showed that combining immunotherapy with a KRAS inhibitor can lead to long-lasting tumor elimination.

Researchers at The University of Texas MD Anderson Cancer Center have uncovered a functional role for KRAS mutations in pancreatic cancer and rapidly translated these findings into a novel therapeutic approach combining a KRAS G12D inhibitor with immune checkpoint inhibitors for early- and late-stage KRAS G12D-mutant pancreatic cancer.

Researchers at The University of Texas MD Anderson Cancer Center have uncovered a functional role for KRAS mutations in pancreatic cancer and rapidly translated these findings into a novel therapeutic approach combining a KRAS G12D inhibitor with immune checkpoint inhibitors for early- and late-stage KRAS G12D-mutant pancreatic cancer. The combination therapy led to durable tumor elimination and significantly improved survival outcomes in preclinical models, leading to the launch of a Phase I cl...